Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 13/20 | 0.41 |
| ▸ | MTTP | P55157 | 13/20 | 0.41 |
| ▸ | SMO | Q99835 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491556 | 0.90 | APOB (0.48) | APOBMTTPSMOSLC6A2 | |
| SCHEMBL6491055 | 0.81 | APOB (0.60) | APOBMTTPSMOALDH1A1 | |
| SCHEMBL6498482 | 0.70 | APOB (0.69) | APOBMTTPSMO | |
| SCHEMBL6498422 | 0.69 | CA1 (0.40) | APOBMTTPSMO | |
| SCHEMBL6499652 | 0.66 | KDR (0.48) | APOBMTTPSMO | |
| SCHEMBL6499683 | 0.65 | PTGS2 (0.42) | ALDH1A1TP53 | |
| SCHEMBL6199831 | 0.64 | CA1 (0.47) | APOBMTTPSMO | |
| SCHEMBL6198196 | 0.64 | CA1 (0.47) | APOBMTTPSMO | |
| SCHEMBL4231484 | 0.64 | CA1 (0.47) | APOBMTTPSMO | |
| Hydrochloric Acid SCHEMBL6203124 | 0.63 | CA1 (0.46) | APOBMTTPSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | APOB 1/4885MTTP 677/4885SMO 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.